Lyra Therapeutics, Inc.

How big is Lyra Therapeutics, Inc.?

As of Jun 18, Lyra Therapeutics, Inc. has a market capitalization of 13.62 million, with net sales of 1.19 million and a net profit of -79.53 million over the last four quarters. The company reported shareholder's funds of 11.59 million and total assets of 66.35 million as of Dec 24.

Market Cap: As of Jun 18, Lyra Therapeutics, Inc. has a market capitalization of 13.62 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Lyra Therapeutics, Inc. reported net sales of 1.19 million and a net profit of -79.53 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 11.59 million and total assets of 66.35 million.

What does Lyra Therapeutics, Inc. do?

Lyra Therapeutics, Inc. is a clinical-stage company developing localized drug delivery solutions for ENT diseases. As of March 2025, it has a market cap of $13.62 million, with net sales of $0 and a net loss of $9 million.

Overview: <BR>Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing and commercializing novel integrated drug and delivery solutions for the localized treatment of ear, nose, and throat (ENT) diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 13.62 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -7.10 <BR>Return on Equity: -1,111.31% <BR>Price to Book: 3.52<BR><BR>Contact Details: <BR>Address: 480 Arsenal St, WATERTOWN MA: 02472-2891 <BR>Tel: 1 617 3734600 <BR>Fax: 1 302 6555049 <BR>Website: https://lyratherapeutics.com/

Should I buy, sell or hold Lyra Therapeutics, Inc.?

Who are in the management team of Lyra Therapeutics, Inc.?

As of March 2022, the management team of Lyra Therapeutics, Inc. includes Dr. Maria Palasis as President, CEO, and Director, and Dr. Nancy Snyderman as a member of the Board of Directors.

As of March 2022, the management team of Lyra Therapeutics, Inc. includes Dr. Maria Palasis, who serves as the President, Chief Executive Officer, and Director. Additionally, Dr. Nancy Snyderman is a member of the Board of Directors.

Is Lyra Therapeutics, Inc. overvalued or undervalued?

As of August 12, 2025, Lyra Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to its high Price to Book Value of 8.31, negative earnings ratios, and a significantly low Return on Equity of -1111.31%, alongside poor stock performance compared to the S&P 500.

As of 12 August 2025, the valuation grade for Lyra Therapeutics, Inc. changed from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its high Price to Book Value of 8.31 and negative EV to EBIT and EV to EBITDA ratios of -0.10, suggesting that it is not generating positive earnings or cash flow. Additionally, the Return on Equity (ROE) is alarmingly low at -1111.31%, further underscoring the company's struggles.<BR><BR>In comparison to its peers, Lyra Therapeutics, Inc. shows stark contrasts; for instance, 2seventy Bio, Inc. has a P/E ratio of 76.93, while Scilex Holding Co. and Generation Bio Co. also reflect negative valuations. The company's stock performance has been dismal, with a year-to-date return of -38.47% compared to the S&P 500's gain of 12.22%, and a staggering -98.94% return over the past five years against the S&P 500's 96.61%. This further reinforces the conclusion that Lyra Therapeutics is currently overvalued.

Is Lyra Therapeutics, Inc. technically bullish or bearish?

As of August 20, 2025, Lyra Therapeutics, Inc. shows a mildly bearish trend due to a bearish daily moving average and monthly Bollinger Band, despite a mildly bullish weekly MACD, with a year-to-date return of -38.47% compared to the S&P 500's 12.22%.

As of 20 August 2025, the technical trend for Lyra Therapeutics, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish daily moving average and a bearish monthly Bollinger Band. The weekly MACD remains mildly bullish, but the overall indicators suggest weakness, particularly with the KST and OBV showing mixed signals. The stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -38.47% compared to the S&P 500's 12.22%.